These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26544127)

  • 21. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

  • 22. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 23. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 24. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 25. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 26. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 27. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 28. Venter's departure sees Celera seek therapies.
    Dennis C
    Nature; 2002 Jan; 415(6871):461. PubMed ID: 11823816
    [No Abstract]   [Full Text] [Related]  

  • 29. UK firms buy into drug design skills of US start-ups.
    Nature; 1995 Feb; 373(6513):372. PubMed ID: 7830777
    [No Abstract]   [Full Text] [Related]  

  • 30. Researchers cut loose as Pfizer and Merck shutter European sites.
    Subbaraman N
    Nat Biotechnol; 2011 Apr; 29(4):299-300. PubMed ID: 21478836
    [No Abstract]   [Full Text] [Related]  

  • 31. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 32. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 33. Biogen Idec restructures, sharpens neurology focus.
    Mitchell P
    Nat Biotechnol; 2011 Jan; 29(1):7-8. PubMed ID: 21221080
    [No Abstract]   [Full Text] [Related]  

  • 34. Bioentrepreneurship 2002: at home in your lab.
    Eisenhardt PE
    Anal Bioanal Chem; 2002 Jan; 372(1):9-11. PubMed ID: 11939216
    [No Abstract]   [Full Text] [Related]  

  • 35. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 36. BIO marches to Congress with growth package in hand.
    Carey K
    Nat Biotechnol; 2011 Sep; 29(9):776-7. PubMed ID: 21904306
    [No Abstract]   [Full Text] [Related]  

  • 37. Wyss Institute to rise in Merck Serono shell.
    Moran N
    Nat Biotechnol; 2013 Mar; 31(3):188. PubMed ID: 23471058
    [No Abstract]   [Full Text] [Related]  

  • 38. Mike Varney.
    Varney M; Mullard A
    Nat Rev Drug Discov; 2015 Mar; 14(3):158-9. PubMed ID: 25677359
    [No Abstract]   [Full Text] [Related]  

  • 39. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 40. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.